ERBB2 and neoplasm: Of note, we observed that dual FASN and HER2 blockade significantly increased in vitro and in vivo therapeutic benefits by decreasing the GFE% of T-refractory cell models and by reducing tumor growth in mice implanted with highly refractory GTR0455 GC cells versus T-based monotherapy.